Business
BELLUS HEALTH ANNOUNCES APPOINTMENT OF MARTIN TOLAR, M.D., Ph.D. TO ITS BOARD OF DIRECTORS
BELLUS HEALTH ANNOUNCES APPOINTMENT OF MARTIN TOLAR, M.D., Ph.D. TO ITS BOARD OF DIRECTORS
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\n Oct. 6, 2010 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\n LAVAL, QC, Oct 6 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS\n Health" or the "Company") is pleased to announce the appointment of\n Martin Tolar, M.D., Ph.D., to the Board of Directors of the Company,\n effective immediately.\n \n\n "We are pleased to welcome Martin Tolar on the Board," said Dr.\n Francesco Bellini, Chairman of the Board of Directors of BELLUS Health.\n "Martin brings with him a wealth of relevant industry expertise and\n knowledge, particularly in the field of Alzheimer's disease where BELLUS\n is currently developing its Phase I drug candidate NRM-8499", he added.\n \n\n Dr. Martin Tolar is President and Chief Executive Officer of NormOxys\n Inc., a private biotechnology company developing oxyrens, a novel class\n of small molecule drugs which enhance the body's ability to deliver\n oxygen more efficiently to hypoxic diseased tissues. Before joining\n NormOxys in 2009, Dr. Tolar was Executive Vice President & Chief\n Business Officer at CoMentis Inc., a private biotechnology company\n engaged in the discovery and development of small molecule drugs to\n treat Alzheimer's disease, macular degeneration and cognition, where he\n led the company's scientific and business growth and negotiated a\n landmark collaboration agreement with Astellas Pharma for CoMentis' beta\n secretase platform, valued at $760 million plus future commercial and\n product...